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11 Abstract Evidence demonstrating that human rhinovirus
12 (HRV) disease is not exclusively limited to the upper air-
13 ways and may cause lower respiratory complications,
14 together with the frequency of HRV infections and
15 the increasing number of immunocompromised patients
16 underline the need for rapid and accurate diagnosis of HRV
17 infections. In this study, we developed the first quantitative
18 real-time nucleic acid sequence-based amplification assay
19 with an internal control using molecular beacon probes for
20 selective and sensitive detection of human rhinovirus ser-
21 otypes. We described a simple method to accurately
22 quantify RNA target by computing the time to positivity
23 (TTP) values for HRV RNA. Quantification capacity was
24 assessed by plotting these TTP values against the starting
25 number of target molecules. By using this simple method,
26 we have significantly increased the diagnostic accuracy,
27 precision, and trueness of real-time NASBA assay. Speci-
28 ficity of the method was verified in both in silico and
29 experimental studies. Moreover, for assessment of clinical
30 reactivity of the assay, NASBA has been validated on
31 bronchoalveolar lavage (BAL) specimens. Our quantitative
32 NASBA assay was found to be very specific, accurate, and
33 precise with high repeatability and reproducibility.
34Keywords Nucleic acid sequence-based amplification 
35Human rhinovirus  Molecular beacon  Internal control 
36RNA detection and quantification
37Introduction
38Human rhinoviruses (HRVs) are the most frequent cause of
39acute upper respiratory tract infections in humans and are
40usually responsible for 30–50% of cases of common cold
41[1–3]. However, they may also be associated with more-
42severe lower respiratory tract infections. Rhinoviruses have
43been isolated from cases of cystic fibrosis, otitis media,
44sinusitis, asthma, exacerbations of chronic obstructive
45pulmonary disease (COPD), and pneumonia, especially in
46children, in the elderly, and in immunocompromised
47patients [4–14]. Evidence demonstrating that HRV disease
48is not exclusively limited to the upper airways and may
49cause lower respiratory complications, together with the
50frequency of HRV infections and the increasing number of
51immunocompromised patients underline the need for rapid
52and accurate diagnosis of HRV infections. Two nucleic
53acid amplification techniques (NAATs) are actually avail-
54able for the detection of HRV: reverse transcription-PCR
55(RT-PCR) [15, 16], and nucleic acid sequence-based
56amplification (NASBA) [17, 18]. NASBA has proven to be
57highly sensitive, specific, and more rapid than RT-PCR
58technique [19, 20]. Currently, only qualitative NASBA kits
59for the detection of HRV are commercially available
60(registered trademarks owned of bioMe´rieux, Marcy
61L’Etoile, France), while there are no quantitative NASBA
62kits. Some quantitative molecular beacon real-time NAS-
63BA assays have been described in the literature, mainly for
64the identification of human immunodeficiency virus (HIV),
65respiratory syncytial virus A and B, influenza A virus
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66 (H1N1), Trypanosoma brucei, Aspergillus fumigatus,
67 Plasmodium species, and Listeria monocytogenes [21–29].
68 However, these real-time NASBA assays use mathematical
69 models for the analysis of results that requires employing
70 of specific complex software calibrated to each target [30].
71 Other quantitative NASBA assays, instead, compute the
72 ratio of the time to positivity (TTP) values for both the
73 target RNA and internal control by using standard curves
74 with a correlation coefficient less than 0.99 (R
2
\ 0.99),
75 index of an insensitive assay [19, 24, 26].
76 Aim of this study was to develop the first quantitative
77 real-time nucleic acid sequence-based amplification assay
78 internally controlled using molecular beacon for selective
79 and sensitive detection of HRV serotypes. Validation and
80 standardization were performed by evaluating diagnostic
81 trueness, precision, and accuracy of real-time NASBA
82 assay.
83 Materials and Methods
84 Viral Isolates and RNA Extraction
85 Prototype human rhinovirus serotype 16 (HRV-16) was
86 obtained from the American Type Culture Collection
87 (ATCC, Manassas, Virginia). Rhinovirus serotype 16
88 (ATCC VR-283), originally isolated from a human clinical
89 specimen, was extracted by using an automatic extractor
90 NucliSENS easyMAG platform (bioMe´rieux, France),
91 according to the manufacturer’s recommendations. One-
92 hundred-microliters of HRV-16 were used for the extrac-
93 tion, RNA was eluted in 25 ll of nuclease-free water and
94 stored at -80C. To evaluate the specificity of the HRV
95 NASBA assay, purified RNA templates from 12 HRV
96 isolates, and 14 selected respiratory viruses other than
97 HRV were used for inclusivity and exclusivity testing
98 (Table 1).
99 In Vitro RNA Transcription
100 Viral cDNA was generated, first by incubation of random
101 primers (600 ng/ll) and dNTPs (10 mM) (Invitrogen) with
102 10 ll of HRV-16 RNA for 5 min at 70C. Subsequently, a
103 mix containing buffer 59 [250 mM Tris–HCl (pH 8.3 at
104 25C), 375 mM KCl, and 50 mM DTT], MgCl2 (25 mM),
105 ImpromII RT (1 U/ll), and Recombinant RNasin
 Ribo-
106 nuclease Inhibitor (40 U/ll) (Promega) was added. The
107 total volume (20 ll) of the reaction mixture was incubated
108 for 5 min at 25C, 60 min at 42C, and 15 min at 70C
109 using 9800 Fast Thermal Cycler (Applied Biosystems,
110 Monza, Italy). cRNA production was carried out using
111 T7-RiboMAX Large Scale RNA Production Systems
112 (Promega, USA) at 37C for 4 h. One-tenth of cRNA
113product was treated with RQ1 RNase-Free DNase (Pro-
114mega, USA) at 37C for 15 min followed by incubation
115with EDTA for 15 min at 65C. HRV-16 cRNA was
116purified using RNAgent kit (Promega, USA) following
117manufacturer’s instructions. HRV-16 cRNA was quantified
118using Quant-iT DNA BR assay on Qubit
TM
fluorometer
119(Invitrogen, Carlsbad, USA), and the number of molecules
Table 1 Evaluation of real-time NASBA specificity with HRV iso-
lates and respiratory viruses other than HRV
Taxon Provider Test
specificity
for:
HRV
Inclusivity testing
Human rhinovirus 1B ATCC VR-1366 ?
Human rhinovirus 2 ATCC VR-482 ?
Human rhinovirus 3 ATCC VR-483 ?
Human rhinovirus 7 ATCC VR-1601 ?
Human rhinovirus 9 ATCC VR-489 ?
Human rhinovirus 16 ATCC VR-283 ?
Human rhinovirus 41 ATCC VR-339 ?
Human rhinovirus 58 ATCC VR-1168 ?
Human rhinovirus 8 QCMD EQA
RV.CV10-02
?
Human rhinovirus 42 QCMD EQA
RV.CV10-01
?
Human rhinovirus 72 QCMD EQA
RV.CV10-03
?
Human rhinovirus 90 QCMD EQA
RV.CV10-05
?
Exclusivity testing
Influenza A virus (H1N1) QCMD EQA
INFRNA10-08
-
Influenza A virus (H3N2) QCMD EQA
INFRNA10-01
-
Influenza B virus QCMD EQA
INFRNA10-06
-
Human parainfluenza virus 1 ATCC VR-94 -
Human parainfluenza virus 2 ATCC VR-92 -
Human parainfluenza virus 3 ATCC VR-93 -
Human parainfluenza virus 4a ATCC VR-1378 -
Human parainfluenza virus 4b ATCC VR-1377 -
Human coronavirus OC43 ATCC VR-1558 -
Human coronavirus 229E ATCC VR-740 -
Human coronavirus NL63 QCMD EQA
RV.CV10-10
-
Human coxsackievirus B4 ATCC VR-184 -
Human respiratory syncytial
virus A
ATCC VR-1540 -
Human respiratory syncytial
virus B
ATCC VR-1400 -
Note: ATCC American type culture collection, QCMD (EQA) quality
control for molecular diagnostics (external quality assessment)
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120 per microliter calculated from the molecular weight of
121 HRV-16 amplicon (70,950 MW) and Avogadro number
122 (6.023 9 10
23). Ten-fold dilutions of RNA standards were
123 generated in order to amplify from 10
8 to 1 copy per reaction,
124 and frozen at -80C until use.
125 Synthesis of Internal Control (IC) RNA
126 For the production of internal control (IC) RNA, we used
127 the human U1A housekeeping gene encoding the ‘‘A’’
128 protein present in the human U1 small nuclear ribonu-
129 cleoprotein (snRNP) particle. To generate the IC RNA, the
130 U1A molecule was extracted from a clinical specimen,
131 precisely from a human bronchoalveolar lavage sample,
132 and subjected to reverse transcription (RT) reaction by
133 using random primers (600 ng/ll) and ImpromII RT (1 U/
134 ll). IC cDNA product was amplified by using adapted
135 NASBA primers containing the T7 RNA polymerase pro-
136 moter site. Briefly, 2 ll of IC cDNA was added to 28 ll of
137 PCR solution containing Flexi Buffer 59, 50 mM MgCl2,
138 1 unit GoTaq
 Hot Start Polymerase (Promega), 200 lM
139 of each dNTP, and 25 lM of each U1A primer. After an
140 initial denaturation step of 2 min at 94C, the first-round
141 PCR amplification was carried out under the following
142 conditions: 95C for 0 s, 58C for 15 s, 72C for 10 s for
143 35 cycles, then one cycle at 72C for 7 min using the 9800
144 Fast Thermal Cycler (Applied Biosystems). PCR product
145 was transcribed in vitro using T7-RiboMAX, as previously
146 described (see ‘‘In vitro transcription’’ in the ‘‘Materials
147 and methods’’ section). Ten-fold dilutions of IC RNA
148 standards were generated in order to amplify from 10
8 to 1
149 copy per reaction.
150 Real-Time NASBA Assay and Data Analysis
151 Primers and molecular beacon probes were obtained from
152 literature [31, 32] (Table 2), synthesized by Eurogentec
153 (Seraing, Belgium), and diluted to a final concentration of
154 100 lmol/l. Moreover, to maximize the oligonucleotides
155 stabilization, we added 60% dimethyl sulfoxide (DMSO)
156 to primers and beacons mixture. The HRV beacon was
157 labeled with FAM at its 50-end and quencher DABCYL at its
158 30-end, while the IC beacon contained a ROX at its 50-end
159 and a DABCYL quencher at the 30-end. The stability and
160 predicted structure of the beacons were analyzed by using
161 the European MFOLD server (http://frontend.bioinfo.
162 rpi.edu/applications/mfold/cgi-bin/dna-form1.cgi). Real-
163 time NASBA reaction was performed on a NucliSens EasyQ
164 analyzer (BioMe´rieux) using the NucliSENS EasyQ Basic
165 Kit Version 2 (bioMe´rieux, Lyon, France) for the amplifi-
166 cation according to the manufacturer’s manual. To obtain
167 the best amplification efficiency, conditions for the real-time
168 NASBA assay were optimized until the best primers,
169beacons, and KCl concentrations were determined. Titra-
170tions of IC RNA (between 10 and 10
6 copies) andHRVRNA
171were performed to determine the optimal amount of internal
172control to generate the greatest dynamic range for the assay
173without interference with the detection of HRV RNA (data
174not shown). As a result, each reaction was run with the
175addition of 10
5 copies of the IC RNA. Briefly, a total volume
176of 10 ll of reaction mixture containing 80 mM KCl and
1770.3 lM of the HRV- and IC-specific primers was incubated
178with 2.5 ll HRVRNA and 2.5 ll IC RNA in the presence of
1790.05 lM of HRV- and IC-molecular beacons at 65C for
1802 min to denature secondary structure RNA. The reaction
181was subsequently cooled to 41C for 2 min to anneal the
182primers before adding 5 ll of enzyme mixture containing
183avian myeloblastosis virus retrotranscriptase, RNase H, and
184T7 RNA polymerase. After a brief centrifugation and gentle
185mixing by tapping, the tubes were then incubated at 41C for
18690 min. To estimate the dynamic range of the real-time
187NASBA assay (range of concentrations over which the
188method performs in a linear manner with an acceptable level
189of trueness and precision), we used HRV standard dilutions
190from 10
8 copies/ll to 1 copy/ll. Sensitivity of NASBA assay
191was determined by the lowest standard dilution consistently
192detectable in replicate reactions at frequency of 100%,
193whereas the limit of detection by the lowest concentration of
194target quantified. Nuclease-free water was included as the
195no-template control (NTC) to serve as a control for back-
196ground fluorescence. The fluorescence signal was measured
197with an interval time of 45 s for each independent reaction at
198two wavelengths using the accompanying NucliSENS
199EasyQ Director software (Version 2.0). Following amplifi-
200cation, a specific fluorescence value was chosen as a positive
201signal (threshold level = 1.1). Using this value for all
202reactions in one experiment, the time that the target and IC
203amplification curves reached the threshold level was
Table 2 Primers and molecular beacons for HRV and IC-U1A real-
time NASBA assay
Primer or MBa Sequence (50-30)
HRVJ P1 AATTCTAATACGACTCACTATAGGGAGb
ACCAMYWTTYTGYSTWGAWAC
HRVJ P2 CTCCGGCCCCTGAATGYGGCT
HRVJMB-FAM CCAAGCcGAYGGGACCRACTACTTTGG
GCTTGG
U1A P1 AATTCTAATACGACTCACTATAGGGb
AGAGGCCCGGCATGTGGTGCATAA
U1A P2 CAGTATGCCAAGACCGACTCAGA
U1AMB-ROX CGTACGcGATGAAAGGCACCTTCGTGGA
CGTACG
a MB, molecular beacons. 50-end of the beacon was labeled with
FAM or ROX, and 30-end was labeled with the nonfluorescent
quencher DABCYL. b T7 RNA polymerase promoter sequence for
NASBA. c Stem sequence for the molecular beacons
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204 recorded as the time to positivity (TTP). HRV TTP values
205 were regressed against the original standard curve to gen-
206 erate a predicted amount of target RNA. In particular, for
207 data analysis, Excel calculation engine was used. NASBA
208 dynamic range was calculated from TTP values regressed
209 against the standard curve by using an Excel spreadsheet that
210 was created ‘‘ad hoc’’ by us. In particular, for each individual
211 HRV standard dilution (from 10
8 copies/reaction to 1 copy/
212 reaction), fluorescent threshold levels of target close to 1.1
213 and values of the corresponding minutes were extrapolated
214 by the NucliSENS EasyQ Director software. Therefore,
215 minutes were normalized to a value of threshold level =
216 1.1, and the natural logarithm of normalized minutes was
217 calculated. Quantification capacity was assessed by plotting
218 the TTP values obtained against the logarithm of the number
219 of target molecules in each dilution and calculating a linear
220 regression.
221 Specificity of Real-Time NASBA Assay
222 The specificity of the developed real-timeNASBAassaywas
223 verified by in silico studies (analytical specificity) against
224 publicly available sequence databases (BLAST alignment
225 software (http://blast.ncbi.nlm.nih.gov/Blast.cgi)) to evalu-
226 ate possible cross-reactions with respiratory viruses other
227 than HRV. Experimental specificity was also verified. In
228 particular, sequences of different respiratory viruses were
229 used for exclusivity testing (Table 1).
230 Validation and Standardization of Real-Time NASBA
231 Assay
232 To determine the performance of HRV NASBA assay, we
233 assessed the diagnostic trueness, precision, and accuracy of
234 the technique. Specifically, precision was assessed by
235 evaluating repeatability and intermediate reproducibility of
236 NASBA assay. To determine the repeatability, several
237 replicates containing the various amounts of HRV RNA
238 were tested. The repeatability was determined by 10-fold
239 serial dilutions of the HRV RNA standards. In particular,
240 we used four different dilutions (10
2, 103, 104, and 105
241 copies/reaction) of quantification standards. Each dilution
242 was analyzed 10 times, with the same method on identical
243 test items in the same laboratory by the same operator
244 using the same equipment. Regarding intermediate repro-
245 ducibility, each dilution was analyzed with the same
246 method on identical test items in 10 different runs per-
247 formed by three different operators using different equip-
248 ment on different days. Moreover, we used the Dixon’s test
249 to examine if one measure from 10 replicate measures that
250 we performed (10
2, 103, 104, and 105) could be rejected or
251 not, and the Shapiro–Wilk’s test to compare these measures
252 against the normal distribution. Statistical data analyses
253were performed using the PASW Statistics version 18.0
254(SPSS Inc., Chicago, Illinois, USA).
255Clinical Specimens
256For assessment of clinical reactivity of the assay, respira-
257tory specimens collected from our Virology Unit of the
258Azienda Ospedaliero-Universitaria San Giovanni Battista,
259Turin, were tested for HRV by real-time NASBA assay.
260Clinical specimens included 33 bronchoalveolar lavages
261(BAL) obtained from 33 transplant patients (M/F, 20/13;
262mean age, 56.2 years; range 21–88). A number of pre-
263cautions were undertaken to prevent the occurrence of
264false-positive results. Each run included control reactions
265lacking template (no-template controls) to test for the
266presence of contamination or the generation of nonspecific
267amplification products under the assay conditions used.
268Results
269Sensitivity of Real-Time NASBA Assay
270Optimal real-time NASBA assay conditions that allowed
271efficient amplification of the HRV target were established.
272Sensitivity and limit of detection of NASBA assay were
273assessed by repeated testing of serial logarithmic dilutions
274of the HRV RNA standards ranging from 10
8 to 1 copy/
275reaction. In particular, HRV NASBA dynamic range was
276calculated from TTP value (time point at which emitted
277fluorescence exceeds the baseline emission) regressed
278against the standard curve by using an Excel spreadsheet
279created ‘‘ad hoc’’ by us (Table 3). Results from linear
280regression show that HRV real-time NASBA assay was able
281to quantify from 10
8 to 10 copies/reaction. The standard
282curve of HRV dilutions plotted versus NASBA amplifica-
283tions (expressed as TPP) is shown in Fig. 1, whereas plots
284for the amplification of HRV standard dilutions (from 10
8 to
28510 copies/reaction), and the optimal amount of IC RNA
286(10
5 copies/reaction), are shown in Fig. 2. The consistency
287of replicates was measured by the correlation coefficient
288(R
2), which indicates the linearity of TPP values plotted in
289the standard curve. The R
2 index for HRV was 0.9948.
290Sensitivity of real-time NASBA assay was determined by
291the lowest standard dilution consistently detectable in rep-
292licate reactions at frequency of 100%. HRV sensitivity was
29310 copies/reaction, whereas the limit of detection for reli-
294able quantification was 1 copy/reaction.
295Specificity of Real-Time NASBA Assay
296Based on the data available at the BLAST alignment
297software, primers were tested in silico for potential
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298 cross-reactivity with respiratory viruses other than HRV,
299 and demonstrated no significant homologies to any other
300 sequences. Moreover, HRV primer and probe set, tested on
301 respiratory viruses, was able to detect only HRV isolates,
302 thus being the inclusivity of 100% (Table 1). The assay’s
303 specificity was further demonstrated by its ability to
304 exclude all respiratory viruses other than HRV listed in
305 Table 1. No positive results were demonstrated for the
306 other respiratory viruses, indicating that this molecular
307 assay is highly specific for HRV isolates, thus being the
308 exclusivity of 100% (Table 1).
309 Validation and Standardization of Real-Time NASBA
310 Assay
311 Diagnostic trueness of HRV real-time NASBA method,
312 defined as the degree of agreement between the average
313 value obtained from a large series of test results and an
314 accepted reference value, was evaluated. To establish the
315 level of trueness and concordance with the assigned value,
316 data from 10 replicate measures of each dilution that we
317performed (10
2, 103, 104, and 105) were analyzed using a
318Student’s t test to compare the mean concentrations from
319each dilution with an accepted reference value. The mean
320concentrations from each dilution for the method are shown
321in Table 4 with the t test results, which indicate the signifi-
322cance of the differences between each experimental mean
323and the assigned value. Analysis of the t statistics showed
324that the method had t-calc values lower than the t-tab value,
325demonstrating a significant trueness of HRV assay.
326Precision of method was expressed as the coefficient of
327variation (CV) in the log10 values of the concentration.
328Repeatability and intermediate reproducibility of HRV
329assay were evaluated over different concentrations ranging
330from 10
2 to 105 copies/reaction from 10 replicate measures
331(n = 10) of each reference viral quantification standard
332within a single run or in 10 different run experiments per-
333formed by three different operators. The precision associ-
334ated with each dilution measurement (10
2, 103, 104, and
33510
5) was assessed by calculation of the CV for each. The
336CVs within a single run (repeatability) ranged from 0.73 to
33713.23%; whereas, the CVs in different runs (intermediate
338reproducibility) ranged from 3.71 to 16.71% (Table 4),
339indicating that the precision of the assay is satisfactory.
340Diagnostic accuracy includes both trueness and preci-
341sion. The measure of accuracy is usually expressed
342numerically in terms of bias (lack of agreement). Accuracy
343shall be within ±25% of the accepted reference value over
344the whole dynamic range, according to document ISO
34516140 [33]. Data for the percentage of inaccuracy HRV
346method are reported in Table 4.
347Clinical Performance of Real-Time NASBA Assay
348The developed real-time NASBA assay was able to detect
349HRV RNA in 7/33 (21.2%) BAL specimens. The TTP
350values of these NASBA-positive samples ranged between
HRV y = -0,0777x + 4,1631
R2 =  0,9948
0
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Fig. 1 Standard curve of HRV real-time NASBA assay. HRV TTP
values were regressed against the standard curve to generate a
predicted amount of target RNA. HRV ln dilutions (108 to 10 copies/
reaction) on x-axis are plotted against ln minutes (TTP) on y-axis. The
coefficient of correlation (R2) was 0.9948. TTP time to positivity, Ln
natural logarithm
Table 3 Excel spreadsheet used to calculate HRV NASBA dynamic range
HRV
dilutions
Threshold Minutes Normalized minutes
threshold 1.1
Ln normalized
minutes (TTP)
HRV ln dilutions
108 1.10476600 15.088 15.02290983 2.709576358 18.4206807
107 1.10571300 18.833 18.73569362 2.930430454 16.1180957
106 1.10279600 21.82917 21.7738249 3.080708556 13.8155106
105 1.11357000 26.3245 26.00370879 3.258239174 11.5129255
104 1.10117700 31.57033 31.53658585 3.451148328 9.21034037
103 1.10275300 39.81483 39.7154331 3.681739855 6.90775528
102 1.10297100 45.81017 45.68677418 3.821808851 4.60517019
10 1.09937600 51.05633 51.0853093 3.933496967 2.30258509
For each individual HRV standard dilution, fluorescent threshold levels close to 1.1 and values of the corresponding minutes were extrapolated
by the NucliSENS EasyQ Director software. Minutes were normalized to a value of threshold level = 1.1, and the natural logarithm (ln) of
normalized minutes was calculated. Quantification capacity was assessed by plotting the TTP values obtained against the logarithm of HRV
dilutions and calculating a linear regression. TTP time to positivity
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351 39 and 51 min when plotted against the standard curve in
352 Fig. 1 (data not shown). All the results were validated by
353 the addition of internal control RNA to rule out inhibition
354 of amplification. In all cases, amplification of the control
355 RNA was observed, thus, confirming that all the negative
356 and positive results are valid. Moreover, all negative con-
357 trol reactions were NASBA negative, demonstrating the
358 absence of amplicon contamination.
359 Discussion
360 Viral respiratory tract infections have been recognized as a
361 predominant cause of human disease. To improve clinical
362 management of such patients, it is important to obtain an
363accurate diagnosis and to identify the causative agent early
364in infection to ensure appropriate treatment. In this study,
365we developed the first quantitative NASBA assay for the
366detection of HRV serotypes. By combining NASBA
367amplification with molecular beacon probes, this assay
368becomes a real-time analysis tool that offers faster results
369than conventional RT-PCR technique. Since NASBA
370amplification involves three separate enzymes each with
371their own kinetic parameters, variability in every measure-
372ment is inevitable [19]. Weusten et al. [30] were the first to
373describe a mathematical model for RNA amplification of
374both target and internal calibrator RNA in a molecular
375beacon-based NASBA reaction to normalize enzyme effi-
376ciency differences between reactions. However, the
377description of this model did not include all of the essential
Fig. 2 Real-time NASBA amplification plots of HRV (WT) standard
dilutions (from 108 to 10 copies/reaction), and the optimal amount of
IC (SC) RNA (105 copies/reaction). TPP (in minutes) and
fluorescence exceeds background are indicated on x- and y-axis,
respectively. WT wild type, IC internal control, SC system control,
TPP time to positivity
Table 4 Statistical summary of
validation and standardisation
of HRV real-time NASBA assay
Ln natural logarithm
Ln 102 Ln 103 Ln 104 Ln 105
Trueness (t test)
Experimental mean concentration 4.18914 6.66043 9.33646 11.44784
Standard deviation 0.55411 0.27162 0.11906 0.08413
t-calc 1.67897 2.03641 2.36935 1.72916
t-tab (n = 10) 2.776 2.776 2.776 2.776
Precision (% coefficient of variation)
Repeatability 13.22732 4.07810 1.27521 0.73493
Intermediate reproducibility 16.71455 3.70736 4.861 5.53251
Accuracy (% bias inaccuracy) 9.03457 3.58098 1.36973 0.56511
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378 parameters needed to operate the model. Consequently,
379 analysis using this model requires software calibrated to
380 each target and is commercially available for only a few
381 specific targets. Here, we describe an alternative method for
382 normalizing NASBA data by using a simple TPP calculation
383 in the presence of an internal control that reduces the vari-
384 ability between replicates and increases the precision,
385 trueness, and accuracy for predicting unknown concentra-
386 tions of HRV RNA. It has been shown that tube to tube
387 variation within NASBA can be normalized with the addi-
388 tion of an internal control in each reaction [34, 35]. In
389 particular, the optimal concentration for the internal cali-
390 brator should be determined as the concentration providing
391 the greatest dynamic range of amplification of both the
392 target and internal control RNA. In our study, a fixed
393 amount of 10
5 copies of the internal calibrator RNA was
394 optimal for the assay reported here (data not shown). Fur-
395 thermore, the addition of an internal control is fundamental
396 to identify false negative results because of reaction failure,
397 and to monitor the effects of unknown sample factors that
398 might interfere with the amplification kinetics. As concerns
399 the importance of primers and KCl for NASBA optimiza-
400 tion, their role has not been emphasized to date. NASBA is
401 an isothermal nucleic acid amplification method able to
402 specifically amplify target RNA by using specific primers in
403 a KCl background. Initially, the concentration of the prim-
404 ers relative to the total concentration of amplifiable RNA is
405 very high, is not rate limiting, and relatively small amounts
406 of primers are consumed in depletion of the initially present
407 pool of RNA copies (linear phase of NASBA process). At
408 some time point, obviously, the primers’ concentrations do
409 become rate limiting, and decline to practically zero. At this
410 time point, the DNA intermediate levels have reached their
411 maximum and RNA production proceeds at high speed.
412 From now on, the only reaction that can proceed is T7 RNA
413 polymerase-mediated formation of RNA from the DNA
414 intermediate templates. This time interval represents the
415 second phase of NASBA process characterized by an
416 exponential kinetics. We observed that high concentrations
417 of primers and KCl elongate the linear phase of NASBA
418 process by shorting the exponential amplification; whereas,
419 low concentrations of primers and KCl promote the expo-
420 nential phase. In particular, in this study we used relatively
421 low concentrations of primers and KCl (0.3 lM and
422 80 mM, respectively) to elongate the exponential phase of
423 NASBA process, and accordingly, to minimize the reaction-
424 to-reaction variation. By using this simple expedient, we
425 have significantly increased our accuracy, precision, and
426 trueness of prediction over the standard TTP calculations. In
427 summary, we describe a simplified method of calculating
428 unknown concentrations of target RNA using an internal
429 calibrator. This method allowed for greater precision,
430 accuracy, and trueness for predicting HRV RNA over the
431standard TTP analysis. In conclusion, we described the first
432real-time NASBA assay capable of accurate quantification
433of HRV RNA making it a valuable tool in the molecular
434diagnostics of HRV serotypes.
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